September 1997 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”
Blocking IL-1 could help treat some hair loss conditions; alopecia affects liver detox systems; spironolactone is better than finasteride for female hair growth; focusing on the catagenhair phase could lead to new alopecia treatments.
User frustrated with lack of results from finasteride and minoxidil for hair loss. Others suggest checking for other health issues, focusing on fitness, and considering alternative treatments.
A 28 year old male experiencing diffuse thinning, chronic dandruff and scalp crust (seborrheic dermatitis), with replies discussing the use of topical fin for hormone imbalances and Nizoral for seb derm.
The post discusses using Sandalore as a potential hair loss treatment, emphasizing precise measurements and safe handling. The user compares Sandalore's effects to Minoxidil and mentions preparing a solution with ethanol and DMSO.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.